JNJ-77242113
janssen,protagonist therapeutics
['psoriasis', 'protagonist ']
positive topline data from the ph2b clinical trial of jnj-2113 (formerly pn-235), the first and only il-23r antagonist peptide in development for moderate-to-severe plaque psoriasis, were presented today at the . read more here: 
Discovering and developing novel therapies through our proprietary technology platform. #biotech #lifesciences #innovation